AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03321890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: oral, 50mg / day,after lunch
Study NCT03321890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: oral, 50mg / day,after dinner
Study NCT03321890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: oral, 10mg / times, once a week,after breakfast
Study NCT03531606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mechnicov probiotics
Description: Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'
Study NCT00027898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT03680105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RJX
Description: RJX is an IV infusion formulation. The appropriate RJX dose is calculated based on mL/kg. The administration dose is prepared by adding the appropriate RJX dose to 0.9% sterile saline such that a constant volume of 100 mL per IV infusion is obtained. Infusion time is 100 mL over 45 minutes (+/- 5 minutes).
Study NCT03531606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'
Study NCT00707486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemcon Dental Dressing
Description: The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
Study NCT00707486 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gauze with Pressure and/or Gelfoam
Description: Common practice for oral surgery patients involves the use of sterile dressing over the extraction site. The subject will provide the pressure by biting down on the sterile gauze. As previously discussed, other practices involve the use of Gelfoam prior to application of sterile gauze.
Study NCT05889169 — intervention group
Intervention type: OTHER
Intervention: Neurorehabilitation
Description: Four to eight weeks motor rehabilitation (500 minutes per week across 6 day per week)
Study NCT02640755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AZD2014
Description: Radiolabelled dual TORC1/TORC2 inhibitor
Study NCT02640755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple dose AZD2014
Description: Dual TORC1/TORC2 inhibitor
Study NCT02640755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Hormonal Agent
Study NCT02640755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Taxane
Study NCT00380406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leuprolide acetate
Study NCT00380406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate
Study NCT02864706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: All patients, independent of their initial randomization in the core study, were followed up as in one single group~Commercially available everolimus (Certican®), oral route, was used.
Study NCT02864706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
Study NCT02864706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
Study NCT02864706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
Study NCT04567953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva collection
Description: Use Spectrum Solutions SDNA1000 or Orasure collection kit or dry tube to collect 1-3 ml of saliva
Study NCT01678560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring every 3 months by face-to-face visits
Description: These patients will be monitored on a 3-month, 6-month, 9-month and 12-month intervals with scheduling face-to-face visits. Adherence and efficacy data will only be assessed by the clinician at these intervals.
Study NCT01678560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Frequent remote monitoring
Description: These patients will be monitored using wireless modems as the method to obtain adherence and efficacy and follow-up phone calls
Study NCT04019236 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: visual analogue scale (VAS),Respiratory distress observational scale (RDOS) and other Nursing care
Description: Distressed patient will be assessed by visual analogue scale(VAS) or respiratory distress observational scale.Nursing interventions will be done according to its causes as giving supplemental O2 therapy, pharmacologic therapy ,initiating positive pressure ventilation or change Ventilator settings (TV, PEEP, Inspiratory pressure ), Improve inspiratory muscle function by Nutrition, positioning or by minimizing use of steroids , clearing airway by Suctioning, Check O2 saturation level frequently and maintain O2 saturation between 95-100%, ,Raising the HOB (Head of the Bed), high Fowler's ,Give pain medications as prescribed or diuretics as ordered and If thick secretions increase oral fluids intake
Study NCT03484689 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness-based cognitive therapy MBCT
Description: 8-week mindfulness-based cognitive therapy
Study NCT00644813 — intervention group
Intervention type: OTHER
Intervention: Scapular with glenoid neck fractures
Study NCT02048657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley Airway Stylet Tool
Study NCT02048657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: introducer-tool
Study NCT00796224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 60 mg/kg azithromycin ER
Description: subjects taken 60 mg/kg azithromycin ER
Study NCT00796224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 mg/kg azithromycin IR
Description: subjects taken 30 mg/kg azithromycin IR (Immediate Release)
Study NCT02777164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIRA device imaging
Description: MIRA Device imaging for adjunctive detection of breast cancer
Study NCT00877734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baclofen
Description: 10 mg Baclofen administered tid for 11 weeks
Study NCT00877734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo administered tid for 11 weeks
Study NCT00877734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRENDA counseling
Study NCT00877734 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: BRENDA counseling
Study NCT00874224 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic left lateral hepatic sectionectomy
Description: laparoscopic left lateral hepatic sectionectomy
Study NCT00874224 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open left lateral hepatic sectionectomy
Description: open left lateral hepatic sectionectomy
Study NCT01547806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim will be administered as a single daily dose in a dose range of 10-16ug/kg/day subcutaneously for 5-7days
Study NCT01547806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor will be given on day 4, 8-10 hours before the day 5 apheresis, dose calculated according to patient weight
Study NCT01547806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: The minimum cluster of differentiation 34 (CD34)+ cell dose that must be collected in order to proceed with a single autologous transplantation is 2 x 106 CD34+ cells/kg.
Study NCT02001922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD integrated care
Description: The intervention will target COPD integrated care, and include a combination of patient-related, professional and organizational elements. It will be centered on patients' needs and focus on self-management education, proactive follow-up (scheduled visits and/or phone contacts), team work, healthcare professionals' training, promotion of pulmonary rehabilitation, physical activity and smoking cessation.
Study NCT01589692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Reduction and Internal Fixation
Description: Internal fixation with a volar locking plating system
Study NCT01589692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External Fixation
Description: External Fixation with a bridging external fixator. Can be done with or without percutaneous pinning.
Study NCT01589692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Pinning
Description: Pinning with any number of Kirschner wires
Study NCT01589692 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Reduction and casting
Description: Closed reduction and immobilization with a cast and/or splint
Study NCT03527303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: 10 minute per day, 8 week digital meditation
Study NCT03145506 — intervention group
Intervention type: DEVICE
Intervention: Multimodal Spectroscopy
Description: optical measurement of excised tissue
Study NCT03964493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092
Description: TNP-2092 100mg/vial
Study NCT03964493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin 1g/vial
Study NCT00591396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIO-101 (Darinaparsin)
Description: Dose Escalation of ZIO-101 (Darinaparsin) given daily for five consecutive days to be repeated every 28 days for up to six months
Study NCT04436887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positioning of polypropylene strips for prophylactic purposes in closing the middle laparotomies to prevent the incisional hernia
Description: Sub-lay mesh supported closure A 4 cm space is created between posterior rectus sheath and rectus muscle, widening 2 cm at each side of midline. Both posterior rectus sheath edges are sutured using a running slowly absorbable suture. Above arcuate line, posterior layer was performed suturing peritoneum and posterior rectus sheath; below arcuate line, posterior layer was performed suturing peritoneum and trasversalis fascia. Anterior layer was performed suturing anterior rectus sheath. A suture length to wound length ratio of 4:1 is recommended. A 4-cm Parietex Progrip Mesh strip was placed between the posterior rectus sheath and rectus muscle with an overlap of at least 2 cm at each side, suture less. In laparotomies >20 cm two stripes of 15 cm each were designed. The midline anterior rectus sheath was closed using a running slowly absorbable suture, covering the mesh. A suture length to wound length ratio of 4:1 is recommended.
Study NCT05430984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic TAPP inguinal hernia repair
Description: Isolation of preperitoneal space will be accomplished to guarantee the mesh flattening with the medial border at the pubic symphysis, the lateral border at the psoas major and anterior superior iliac spine, superior border at least 3 cm above the conjoined tendon, medial inferior border 3 cm below the pectineal ligament, and lateral inferior border to permit perietalization of the spermatic cord (6-8 cm isolation of the hernia sac and spermatic cord).~For the mesh fixation group, the mesh will be fixed to the abdominal wall using suture, spiral tacks, whereas for the non-fixation group it will be left as it is and the operation will be concluded. A mesh measuring 15x10cm is placed in the preperitoneal space and fixed using limited numbers of tacks or suture. In some cases, based on body habitus, a slightly smaller mesh could be used. The peritoneum will be closed over the mesh.
Study NCT03453801 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®
Description: Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine): The pediatric dose (6-35 months) will be supplied in a prefilled, single dose syringe, 0.25 mL (no preservative). Each 0.5 mL dose of Fluzone® Quadrivalent (36 months-adult) will be supplied in a prefilled, single dose syringe, 0.5 mL (no preservative). Both formulations given IM.
Study NCT03405974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin (acetylsalicylic acid)
Study NCT03405974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03966664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.
Description: Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.
Study NCT03966664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood
Description: Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.
Study NCT03966664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biomolecular analysis of plasma proteins.
Description: Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.
Study NCT01687049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Red yeast rice
Study NCT03167827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
Study NCT03167827 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
Study NCT03167827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isoflavone
Description: Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
Study NCT03167827 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Daily supplementation in 1 capsule per day containing starch of corn.
Study NCT00821054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Treatment A: one dose of 1250mg lapatinib 1 hour before starting a low-fat breakfast; Treatment B: one dose of 1250mg lapatinib 1 hour after finishing a low fat breakfast; or Treatment C: one dose of 1250mg lapatinib 1 hour after finishing a high-fat breakfast.
Study NCT03453801 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist®
Description: FluMist® Quadrivalent: live, attenuated influenza virus vaccine quadrivalent, given by intranasal spray
Study NCT00040768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT03869086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Freeze dried blueberry powder
Description: 36 g of freeze-dried blueberry powder to be mixed with milk and served together with an energy-dense meal.
Study NCT03869086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anthocyanin free, sugar-matched placebo
Description: 36 g of isocaloric placebo, matched for sugars to be mixed with milk and served together with an energy-dense meal.
Study NCT04673682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D309
Description: D309(Testosterone) 1 vial, Once, IM injection
Study NCT04673682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-845
Description: CKD-845(Testosterone) 1 vial, Once, IM injection
Study NCT01170013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-up
Description: Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use
Study NCT01170013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent psychoeducation
Description: Two sessions of psychoeducation for parents regarding adolescent risk behaviors. especially substance use
Study NCT02563106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN-004
Study NCT02563106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04141124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing exercise/HRV-biofeedback
Description: 5 min of relaxing breathing, coupled with biological feedback.
Study NCT04141124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxing Breathing
Description: 5 minutes of relaxing breathing guided by a computer helping to follow inspiration and expiration.
Study NCT04141124 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: 5 minutes of reading fictitious biological medical results
Study NCT01557361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated RRT initiation
Description: A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
Study NCT01557361 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard RRT initiation
Description: Patients will be carefully followed over a period of 7 days to identify potential indications for RRT. The trial team will ask that the clinical team consider RRT initiation if there are:~I. Criteria for persistent AKI (serum creatinine has not declined by more than 50% from value recorded at time of eligibility) AND~II. At least one of the following indications for RRT initiation:~1. Serum potassium ≥6.0 mmol/L, or~2. Serum bicarbonate ≤ 10 mmol/L, or~3. Evidence of severe respiratory failure, based on a PaO2/FiO2 \<200 and bilateral infiltrates on the chest x-ray, or~4. By 72 hours after randomization, creatinine has not declined by more than 50% from that recorded at the time of randomization
Study NCT02418481 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Description: DC-CIK cells will be used against tumor cells.
Study NCT02418481 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T Cell
Description: γδ T cells will be used against breast tumor.
Study NCT03680105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.
Study NCT00492817 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.
Study NCT01439269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention
Description: Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
Study NCT01439269 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Nurture Intervention
Description: Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
Study NCT03597776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Bolus of lidocaine will be given over 5 minutes before skin incision
Study NCT03597776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Bolus of saline will be given over 5 minutes before skin incision